Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 October 2019 | Story Leonie Bolleurs | Photo Anja Aucamp
Dr Brain van Soelen and Prof Pieter Meintjies
UFS scientists, Prof Pieter Meintjes and Dr Brian van Soelen, are part of the prestigious H.E.S.S. collaboration that recently published in Nature Astronomy.

Think of an object with a mass exceeding that of the Sun, squeezed into a volume of a sphere with the radius of a city like Bloemfontein. This very dense, compact object, known as a pulsar, is also a great source of energy. According to Physics Professor, Prof Pieter Meintjes, this pulsar (neutron star produced in supernova explosion) is also a key element of a recently submitted paper in Nature Astronomy.

Prof Meintjes and Dr Brian van Soelen, Senior Lecturer, both from the Department of Physics at the University of the Free State (UFS), were part of the High Energy Stereoscopic System (H.E.S.S.) collaboration of 220-plus scientists worldwide who worked on the paper Resolving the Crab pulsar wind nebula at tera-electronvolt energies, published in the prestige journal Nature Astronomy. 

According to Prof Meintjes, the fact that the paper was accepted for publication in Nature Astronomy testifies of the importance of this finding in the high-energy astrophysics community.

Powerful generators of electricity

He elaborates on the study: “The name pulsar originates from the fact that rotating neutron stars produced in supernova explosions produce beams of radiation, much like a lighthouse. Every time the beam intersects the observer’s line of sight, the observer receives a pulse of radiation.”

“As a result of this enormous mass squeezed into a small volume, these objects have the same density as that of an atomic nucleus. These objects (very dense pulsars) spin very rapidly and have enormous magnetic fields; for example, the pulsar at the centre of the Crab Nebulae spins around its axis once every 33 milliseconds (millisecond: one thousandth of a second) and possesses a magnetic field strength of the order of one tera-Gauss (tera – million x million). For comparison, the average strength of the Earth’s magnetic field is 0.5. Gauss and the magnetic field strength on the Sun ranges between 1 000 and 4 000 Gauss.”

“Because of this very super-strong rapid-spinning magnet, enormous electric fields are induced that can accelerate particles such as electrons and protons to energies in excess of one tera-electronvolt (optical light that are emitted by an ordinary lightbulb has energies of the order of one electronvolt).”

Prof Meintjes continues: “This means that these fast-rotating neutron stars are extraordinary powerful generators of electricity, which fills the surrounding cloud (supernova remnant) with super-high energy-charged particles that can produce, in turn, very high energy gamma rays through various processes such as synchrotron radiation and inverse-Compton radiation, to name a few.”

H.E.S.S. collaboration 

Above one tera-electronvolt, the gamma rays are detected by huge ground-based telescopes such as H.E.S.S., utilising the Earth’s atmosphere.

“When these high-energy gamma rays enter the atmosphere, they produce showers of super-relativistic particles that produce Cherenkov light – detected by the telescope. The technique is called the Atmospheric Cherenkov Technique (ACT).”

HESS
The High Energy Stereoscopic System. (Photo: Supplied)

“The H.E.S.S. gamma-ray collaboration is but one collaboration that has studied this source intensively over the past couple of decades or so.  Being the most powerful gamma-ray telescope facility currently operational, very careful analysis of the data managed to reveal that the gamma-ray emitting region inside the nebula is about 10 times bigger in size than the region where the x-rays are emitted within the nebula.” 

“This has solved a long-standing question as to how big the gamma-ray emitting region within these supernova remnants are, compared to the region where the x-rays, for example, originates,” says Prof Meintjes. 

Both Prof Meintjes and Dr Van Soelen are members of this prestigious H.E.S.S. collaboration. Their participation in this project, together with scientists from universities such as the University of Oxford, the University of Leicester, and the University of Bordeaux, opens up valuable research opportunities for UFS postgraduate students to enter the international stage and interact with the best scientists in the world.

They are also members of the editorial board responsible for the internal review of research papers before being submitted to more prestigious journals, for example, Nature Astronomy. Dr Van Soelen is also a coordinator of multi-wavelength follow-up observations within the H.E.S.S. collaboration. 

This is the second time that Prof Meintjes published in Nature Astronomy. Previously, he was co-author of a paper on emission from a white dwarf pulsar, showing that fast-rotating white dwarf stars could in fact mimic emission from neutron star pulsars. He developed the theoretical model reported in that paper, explaining the multi-wavelength emission from radio to X-ray energies.


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept